Skip to content

Released Nov 8, 2024, after the close

10-Q filed Nov 8, 2024, 39 days after period end · 0000950170-24-124036

Q3 2024 · 10-Q
Revenue—
Net Income-$2.24MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$40.15N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$1,796,686N/M
Operating Cash Flowderived-$9,256,984N/M
Free Cash Flowderived-$9,274,672N/M

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Net Income-$2.24M-$2.63M-$1.17M-$3.04M
EPS Diluted-$40.15-$9.94-$1.91-$0.48

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR